Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.NicOx, a pharmaceutical company, has completed patient recruitment for its ongoing phase 2b study of BOL-303259-X, conducted by its partner Bausch + Lomb, to treat glaucoma.
Subscribe to our email newsletter
BOL-303259- X, a NO-donating prostaglandin F2-alpha analog, helps lower intraocular pressure (IOP) through a dual mechanism of action.
The study will evaluate the most effective dose of BOL-303259-X, administered in the evening to patients with open-angle glaucoma or ocular hypertension, for the reduction of IOP.
According to Bausch + Lomb, the study is likely to conclude by the end of December 2011, the results of which will be presented in the first quarter of 2012.